U.S. markets closed

COMPASS Pathways plc (CMPS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
35.80-1.36 (-3.66%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close37.16
Open37.66
Bid35.36 x 2200
Ask36.79 x 900
Day's Range35.60 - 37.66
52 Week Range22.51 - 61.69
Volume274,895
Avg. Volume396,198
Market Cap1.313B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.55
Earnings DateMar 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est70.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference
      GlobeNewswire

      COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference

      London, UK, April 09, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that George Goldsmith, Chairman, CEO and Co‑founder, and Lars Wilde, President, Chief Business Officer, and Co‑founder, will present a corporate update at 8:00am ET on 15 April at the 20th Annual Needham Virtual Healthcare Conference. Members of the COMPASS management team will also be holding 1:1 investor meetings. A live audio webcast of the presentation will be available on the "Events" page of the Investors section of the COMPASS website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.compasspathways.com. -Ends- About COMPASS Pathways COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing. www.compasspathways.com Contacts: Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024 Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401-290-7324 Attachment CMPS Needham Conference Participation - 4.8.21

    • COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors
      GlobeNewswire

      COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors

      COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors London, UK – 1 April 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has appointed Wayne J Riley MD to its Board of Directors. Dr Riley is President of the State University of New York (SUNY) Downstate Health Sciences University, Brooklyn, where he holds tenured professorships in internal medicine, and health policy and management. A primary care physician and an academic, he has more than 25 years of experience encompassing clinical and academic medicine, research programme oversight, biotechnology, primary care, public health, healthcare management and policy, healthcare quality, academic health science centre administration, and government service. “We are delighted to welcome Wayne to the COMPASS Board,” said George Goldsmith, CEO and Co-founder of COMPASS Pathways. “He has dedicated his career to patients and to improving healthcare services. At COMPASS, we want to transform the patient experience in mental health care and to give people options. We look forward to benefitting from Wayne’s breadth of expertise as we continue to advance our evidence-based research and to work towards our vision of a world of mental wellbeing." Dr Riley said, “I am honoured to join the Board of COMPASS Pathways at this critical time when it is more important than ever to develop novel, effective treatments for depression and other mental health conditions. I look forward to working with the Board and the management team and contributing to advancing COMPASS’s quest to improve the lives of millions of patients worldwide.” In addition to his position at SUNY Downstate Health Sciences University, Dr Riley is also Chairman of the Board of the New York Academy of Medicine, an elected member of the US National Academy of Medicine, a Commissioner of the US Medicare Payment Advisory Commission, and President of the Society of Medical Administrators. He is a President Emeritus of the American College of Physicians (ACP). Dr Riley is a member of the Board of Directors of HCA Healthcare Inc, a learning health system comprising 180 hospitals and more than 2,000 sites of care in the US and in the UK, where he serves as Chair of the Patient Safety & Quality Committee and a member of the Audit & Compliance and Nominating & Corporate Governance Committees. He previously served as a Director of Vertex Pharmaceuticals. He holds a BA from Yale University, an MPH from the Tulane University School of Public Health and Tropical Medicine, an MD from the Morehouse School of Medicine, and an MBA from Rice University. -Ends- About COMPASS Pathways COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, US. Our vision is a world of mental wellbeing. www.compasspathways.com Availability of other information about COMPASS Pathways Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Forward-looking statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, COMPASS’s business strategy and goals, COMPASS’s ability to continue to advance its research, and COMPASS’s expectations regarding the benefits of its psilocybin therapy. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: preclinical research and clinical development is lengthy and uncertain, and therefore our preclinical studies and clinical trials may be delayed or terminated, or may never advance to or in the clinic; and those risks and uncertainties described under the heading “Risk Factors” in COMPASS’s annual report on Form 20-F filed with the US Securities and Exchange Commission (SEC) on 9 March 2021 and in subsequent filings made by COMPASS with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS’s current expectations and speak only as of the date hereof. Enquiries Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024 Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7423

    • Psyched: Compass' New Patents, Cure Extends DEA License, Andrew Yang Supports Psilocybin in NYC
      Benzinga

      Psyched: Compass' New Patents, Cure Extends DEA License, Andrew Yang Supports Psilocybin in NYC

      Compass Secures 2 New Patents In the midst of a public debate about the right use of patents in the psychedelics sector, Compass Pathways (NASDAQ: CMPS) was granted two new patents by the US Patent and Trademark Office. Compass came under scrutiny last month for applying to a series of patents for methods which were standard practice in psychedelics-assisted psychotherapy decades before the company was founded. On Tuesday, Compass received recognition for one patent, to the rights to crystalline psilocybin formulations and methods using those formulations for the treatment of major depressive disorder. Another patent, granted one week earlier, covers oral dosage forms of crystalline psilocybin and methods of treating major depressive disorder. “These patents are a critical milestone in our efforts to establish a new evidence-based option to help patients with depression in the US,” said George Goldsmith CEO and co-founder of Compass. "Through these grants, the USPTO has recognised our innovations. These decisions enable us to continue to do the highest quality clinical research and bring potentially life-changing care to patients who might benefit from this therapy." The patents announced by Compass in this occasion are not the main focus of controversial claims against the company, which include claiming patents on soft furniture, accompanying music and basic bedside accompaniment from therapists. Cybin Is Pushing 2 New Molecules Towards Clinical Trials Cybin (OTCQB: CLXPF), a developer of second generation psychedelic molecules, completed a new pre-clinical trial, defining the company’s decision to settle on two drug candidates for R&D. CYB003 and CYB004 are two proprietary molecules that Cybin is researching through studies that will eventually allow the application of Investigational New Drug status with the FDA, a necessary step to begin clinical trials. While the company has not disclosed the specific qualities of these new compounds, it has stated that its “development thesis is based on the need to create commercially viable drugs to meet the needs of patients and to easily integrate into the medical ecosystem without the need of overly disrupting a practitioner and/or a patient’s busy schedule.” Andrew Yang Supports Psilocybin Legalization In New York Former presidential candidate Andrew Yang expressed his position on the decriminalization of psilocybin in New York City. Yang is currently a declared candidate for the 2021 New York City mayoral election, to be held in June of this year. “I’m for legalization of psilocybin mushrooms, and I’m open to the public policy impact of legalizing other substances,” the candidate said in a recent live forum, as per Marijuana Moment. Yang also favors “total decriminalization of cannabis and marijuana,” and is open to the public policy impact of legalizing other substances, including opioids. Cure Lands DEA License For Psychedelics CURE Pharmaceutical Holding Corp. (OTCQB: CURR), a company researching various drug delivery methods for psychoactive molecules, extended its Schedule 1 DEA license to include several psychedelic compounds. The company’s existing DEA license, which until now covered the manufacture of cannabinoid-based pharmaceuticals, now includes LSD, MDMA, and psilocybin for the treatment of mental health conditions. “This license will allow us to build out our previously announced psychedelics program safely and legally, expanding our specialty pharmaceutical pipeline and opening new doors to research advancement,” said CURE Chief Executive Rob Davidson. See more from BenzingaClick here for options trades from BenzingaPsyched: The Patents Dilemma, Compass 2020 Earnings, New Psilocybin Bill In NY© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.